Will The Pendulum Swing Back In IPR Proceedings?
Last month, the U.S. Patent and Trademark Office's Patent Trial and Appeal Board issued three decisions invalidating patents that protect Genzyme Corp.'s drug Myozyme for Pompe disease in inter partes review...To view the full article, register now.
Already a subscriber? Click here to view full article